<DOC>
	<DOCNO>NCT02193815</DOCNO>
	<brief_summary>This vehicle comparator control Proof Mechanism ( PoM ) trial evaluate effect psoriasis disease activity safety topically apply PF 06263276 subject psoriasis vulgaris .</brief_summary>
	<brief_title>A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Healthy male and/or female subject age 18 year old , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test . Subjects psoriasis vulgaris chronic stable phase plaque area mild moderate severity sufficient six treatment field locate three plaque area . The target lesion ( ) trunk extremity ( exclude palms/soles ) . Psoriatic lesion knee elbow use target lesion . Subjects psoriasis guttata , psoriasis punctata , psoriasis erythrodermatica , psoriasis arthropathica pustular psoriasis . Treatment systemic medication opinion investigator might counter influence trial aim ( include anti psoriasis medication , eg , corticosteroid , cytostatics retinoids ) medication know provoke aggravate psoriasis ( eg , beta blocker , anti malarial drug , lithium ) phototherapy/psoralen+UVA ( PUVA ) within 4 week precede treatment phase trial trial . Treatment locally act medication ( include antipsoriasis medication like vitamin D analogue , dithranol ) within 4 week treatment phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>plaque</keyword>
	<keyword>vulgaris</keyword>
	<keyword>phase 1</keyword>
	<keyword>randomize</keyword>
	<keyword>double-blind</keyword>
	<keyword>topical</keyword>
	<keyword>safety</keyword>
</DOC>